-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $105

Benzinga·08/07/2026 21:05:11
Listen to the news
TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $96 to $105.